Bo Huang

Bo Huang

Pfizer Inc. - New York / United States
Medical and Health Sciences / Biostatistics
AD Scientific Index ID: 4392087
-
person_outline Bo Huang's MOST POPULAR ARTICLES
1-) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinomaRJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ...New England Journal of Medicine 380 (12), 1103-1115, 201916242019
2-) Avelumab maintenance therapy for advanced or metastatic urothelial carcinomaT Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ...New England Journal of Medicine 383 (13), 1218-1230, 20209112020
3-) Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaA Ribas, R Kefford, MA Marshall, CJA Punt, JB Haanen, M Marmol, ...Journal of clinical oncology 31 (5), 616, 20138692013
4-) Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinomaTK Choueiri, RJ Motzer, BI Rini, J Haanen, MT Campbell, B Venugopal, ...Annals of Oncology 31 (8), 1030-1039, 20204272020
5-) Phase II study of the anti-cytotoxic T-lymphocyte–associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancerKY Chung, I Gore, L Fong, A Venook, SB Beck, P Dorazio, PJ Criscitiello, ...Journal of Clinical Oncology 28 (21), 3485-3490, 20103532010